These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30847645)

  • 21. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy.
    Katsuno M; Adachi H; Doyu M; Minamiyama M; Sang C; Kobayashi Y; Inukai A; Sobue G
    Nat Med; 2003 Jun; 9(6):768-73. PubMed ID: 12754502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA).
    Suzuki K; Kastuno M; Banno H; Sobue G
    Neuropathology; 2009 Aug; 29(4):509-16. PubMed ID: 19486304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
    Katsuno M; Adachi H; Tanaka F; Sobue G
    J Mol Med (Berl); 2004 May; 82(5):298-307. PubMed ID: 15133611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five year follow up of a patient with spinal and bulbar muscular atrophy treated with leuprorelin.
    Shimohata T; Kimura T; Nishizawa M; Onodera O; Tsuji S
    J Neurol Neurosurg Psychiatry; 2004 Aug; 75(8):1206-7. PubMed ID: 15258239
    [No Abstract]   [Full Text] [Related]  

  • 26. Castration-resistant prostate cancer diagnosed during leuprorelin treatment for spinal and bulbar muscular atrophy.
    Yanase A; Sugihara T; Akimoto T; Yokoyama H; Kamei J; Fujisaki A; Ando S; Naoi T; Morita M; Fujimura T
    IJU Case Rep; 2022 Jul; 5(4):251-254. PubMed ID: 35795131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
    Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
    Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy.
    Mitsumoto H
    J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1004-1005. PubMed ID: 28794153
    [No Abstract]   [Full Text] [Related]  

  • 29. Current status of treatment of spinal and bulbar muscular atrophy.
    Tanaka F; Katsuno M; Banno H; Suzuki K; Adachi H; Sobue G
    Neural Plast; 2012; 2012():369284. PubMed ID: 22720173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.
    Weydt P; Sagnelli A; Rosenbohm A; Fratta P; Pradat PF; Ludolph AC; Pareyson D
    J Mol Neurosci; 2016 Mar; 58(3):379-87. PubMed ID: 26572537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Swallowing markers in spinal and bulbar muscular atrophy.
    Banno H; Katsuno M; Suzuki K; Tanaka S; Suga N; Hashizume A; Mano T; Araki A; Watanabe H; Fujimoto Y; Yamamoto M; Sobue G
    Ann Clin Transl Neurol; 2017 Aug; 4(8):534-543. PubMed ID: 28812043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leuprorelin acetate depot in advanced prostatic cancer: a phase II multicentre trial.
    Rizzo M; Mazzei T; Mini E; Bartoletti R; Periti P
    J Int Med Res; 1990; 18 Suppl 1():114-25. PubMed ID: 2108883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost analysis of leuprorelin acetate in Japanese pre-menopausal breast-cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Kurebayashi J
    J Med Econ; 2017 Nov; 20(11):1163-1169. PubMed ID: 28782387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
    Kienle E; Lübben G
    Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
    Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
    J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
    Berges R; Bello U
    Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.
    Yamada S; Hashizume A; Hijikata Y; Inagaki T; Ito D; Kishimoto Y; Kinoshita F; Hirakawa A; Shimizu S; Nakamura T; Katsuno M
    Ann Clin Transl Neurol; 2022 Nov; 9(11):1702-1714. PubMed ID: 36208052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding.
    Hutchon DJ
    BJOG; 2000 Oct; 107(10):1323-4. PubMed ID: 11028593
    [No Abstract]   [Full Text] [Related]  

  • 39. Tongue pressure as a novel biomarker of spinal and bulbar muscular atrophy.
    Mano T; Katsuno M; Banno H; Suzuki K; Suga N; Hashizume A; Araki A; Watanabe H; Tanaka S; Yamamoto M; Sobue G
    Neurology; 2014 Jan; 82(3):255-62. PubMed ID: 24353334
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.